A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany

• Status: Completed
• Trial end date: 2017-07-05
• Target enrollment: 0
• Participant gender: All

Summary

DOL-ART is a multi-center, prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. The primary study objective is a descriptive characterization of the frequency of therapeutic monitoring measures in HIV-infected patients under dolutegravir-containing ART in routine daily practice in Germany.

The study is designed to enroll approximately 400 patients. There are no protocol-mandated visits or procedures associated with the study. Each patient is expected to participate for a maximum of 3 years or until premature discontinuation (i.e., discontinuation of dolutegravir, due to death, withdrawal of consent, lost to follow-up).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ViiV Healthcare
• Collaborator: GlaxoSmithKline
• Treatments: Dolutegravir

Criteria

Inclusion Criteria:

• Documented HIV infection

• Age ≥ 18 years

• Decision for the first initiation of dolutegravir as part of an ART by the attending physician irrespective of inclusion in this observational study

• Prior to the start of this study, the patient must have been receiving a dolutegravir-containing ART for at least 4 weeks

Exclusion Criteria:

• Discontinuation of dolutegravir as part of an ART prior to the start of the study documentation

• Participation in a clinical trial during this study

• Participation in a clinical trial or compassionate use program with dolutegravir being or having been part of the investigational medication